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www.pnas.org/cgi/doi/10.1073/pnas. 1903216116 Table S1 . Indications that support the relevance of 'αS 3K' for modeling synucleinopathyrelevant phenotypes and αS dyshomeostasis. Table S2 . Parameters, clean-up and filters used for each analysis job performed by the IncuCyte software. Table S3 . Antibodies, references, host and dilution used. . mCherry and total αS-3K::YFP levels after drug treatment and induction. A) Toxicity/growth of cells treated with 9 published modifiers of αS biology. Toxicity of drugs was evaluated via the ratio of mCherry signal 24 h after induction over mCherry signal right after induction and is expressed relative to DMSO control (n=4, one way ANOVA including Dunnett's multiple comparison test). B) WB for αS-3K::YFP and GAPDH after treatment with 9 9 published modifiers of αS biology (and GAPDH as a loading control). C) Quantification of the 15G7 signal for αS-3K::YFP normalized to GAPDH (n=9, Brown-Forsythe and Welsh ANOVA including Dunnett's T3 multiple comparison test). D) Toxicity/Growth of cells treated with 5 SCD inhibitors. Toxicity of drugs was evaluated via the ratio of mCherry signal 24 h after induction over mCherry signal right after induction and is expressed relative to DMSO control (n=4, one way ANOVA including Dunnett's multiple comparison test). E) WB for αS-3K::YFP and GAPDH after treatment with 5 SCD inhibitors (and GAPDH as a loading control). F) Quantification of the 15G7 signal for αS-3K::YFP normalized to GAPDH (n=9, one way ANOVA including Dunnett's multiple comparison test). 5 ratio) for 6 h. Cells were induced, and inclusion formation was followed for 24 h (normalized to constitutive mCherry and expressed as % of BSA only control, n = 6). B) Analogous to A, but 285 µM for all FAs (except OA at 100 µM). Top: inclusions rel. to control. n = 18; one-way ANOVA, Dunnett's multi comparison test. Below: WB for αS and GAPDH, plus quantification (norm. to GAPDH, n=6; one-way ANOVA, Dunnett's multi comparison test). C) M17D/αS-3K cells plated without FBS and treated with the indicated FAs for 24 h. WB quantification of pS129:total αS (norm. to control, n = 15; one-way ANOVA, Dunnett's test). D) Analogous to C, but 1 mM DSG intact-cell crosslinking. WB for total αS (mAb 15G7) and DJ-1 control. Quantification of αS60:14 and DJ-1 dimer:monomer (norm. to control, n = 6; One-way ANOVA, Tukey's test. , or αS-E46K (C) were differentiated into iNs for 18 days. At day 18, they were fixed and stained for total αS (mab 15G7), MAP2, NeuN, and β3-tubulin. Scale bar = 50 µm. Fig. S11 . SCD inhibitors A939572 and MF-438 increase αS60:αS14 ratios in αS-E46K expressing human neurons. Human induced pluripotent stem cells (line BR2132) expressing αS-E46K were differentiated into iNs for 14 days, then treated for 4 days with 10 µM of A939572, MF-438 or DMSO control (media replaced, and fresh drugs added after 2 d). At day 18, intact-cell crosslinking was performed using 1mM DSG; PBS/1% TX-100 lysates. WB for αS (mAb 15G7) and DJ-1. Quantification of αS60:14 and DJ-1 dimer:monomer ratios (normalized to DMSO, n = 6, One-way ANOVA including Dunnett's multi comparison test). 
